HealthCap — 2018 Investments

3 investments dated 2018 · listed companies and verified rows first · show all

BioClin Therapeutics inMay 2018

BiotechSan Leandro, US

Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)in Stephen W. Lau(President, Chief Executive Officer, and Treasurer)in Kenneth Schwartz(Executive Officer)in Eric Yuen(Executive Officer)in Marten Steen(Director)in

Co-investorsEQT Life Sciences Inkef Sectoral Asset Management Sofinnova Ventures Ysios Capital

Modus Therapeuticsmodustx.comJul 2018

Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.

Biotech

PRECIRIX NVprecirix.comSeries A · Nov 2018 · $42M

Co-investorsBioMedPartners Inkef Pontifax Venture Capital V-Bio Ventures Forbion

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.